Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
BP4 S.r.l., a ten percent owner of Milestone Scientific Inc. (NASDAQ:MLSS), has sold 64034 shares of common stock over two days, according to a Form 4 filing with the Securities and Exchange Commission. The sales occurred at prices ranging from $0.4398 to $0.4527, resulting in a total transaction value of $28472. The transactions come as the stock has declined over 52% in the past six months, with the company currently valued at approximately $34 million.
On October 20, 2025, BP4 S.r.l. disposed of 24034 shares at a price of $0.4527 per share. Following this transaction, the entity still held 9131192 shares. The next day, October 21, 2025, BP4 S.r.l. sold an additional 40000 shares at $0.4398 per share. After this second transaction, their holdings decreased to 9091192 shares. According to InvestingPro, the company’s overall financial health score is rated as weak, with concerning cash burn rates.
The sales were executed directly by BP4 S.r.l. The filing was signed by Dr. Pedro Palau, Liquidator, on October 23, 2025. For deeper insights into insider transactions and comprehensive analysis, including 6 additional ProTips, check out the full research report available on InvestingPro.
In other recent news, Milestone Scientific reported its Q2 2025 financial results, showing a slight miss in earnings and a revenue shortfall compared to forecasts. The company’s earnings per share (EPS) recorded a loss of $0.02, missing the anticipated loss of $0.01, while revenue reached $2.3 million, falling short of the projected $2.6 million. Additionally, Milestone Scientific received a notice from NYSE American for non-compliance with listing standards, requiring them to submit a compliance plan by November 7, 2025. In corporate governance developments, Milestone Scientific appointed Dr. Dawood Sayed, a leader in pain medicine, to its Board of Directors. The company also received continued support from Benchmark, which maintained its Speculative Buy rating and a price target of $1.25, highlighting progress in the Medicare market for its CompuFlo System. Despite the earnings miss, the company ended the second quarter with $1.3 million in cash and no debt, according to Benchmark’s analysis. Milestone Scientific has also achieved coverage from three of the twelve Medicare Administrative Contractors for its pain management system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.